JACC:儿童心脏支持技术为心脏移植提供了有力保障

2018-07-21 MedSci MedSci原创

小儿心室辅助装置(VAD)在近二十年来发展迅速。本研究的目的旨在描述VAD的发展及其支持下的儿童心脏移植(HTx)。本研究的数据来自小儿心脏移植研究数据库,比较了VAD支持下的小儿心脏移植和由体外膜肺氧合(ECMO)转至VAD支持下的儿童心脏移植。最终共纳入了5145例儿童心脏移植患者,其中995例(19.3%)是在VAD支持下进行的。与由ECMO转至VAD的患者(164例)相比,直接首次装配VA

小儿心室辅助装置(VAD)在近二十年来发展迅速。本研究的目的旨在描述VAD的发展及其支持下的儿童心脏移植(HTx)。

本研究的数据来自小儿心脏移植研究数据库,比较了VAD支持下的小儿心脏移植和由体外膜肺氧合(ECMO)转至VAD支持下的儿童心脏移植。最终共纳入了5145例儿童心脏移植患者,其中995例(19.3%)是在VAD支持下进行的。与由ECMO转至VAD的患者(164例)相比,直接首次装配VAD患者(821例)的年龄更大,患心肌病的比率更大。在仅有VAD的患者中,有79%接受了HTx,14%死亡,在由ECMO转至VAD的患者中,69%患者接受了HTx,24%出现死亡。在装有VAD的患者中,早期有79%的患者年龄大于10岁,但近期该比率下降至34%。总体来看,2年和20年生存率在VAD支持组和无VAD支持组之间无明显差异。心脏移植术后的预后在持续装配VAD患者中比短暂性VAD患者更好,而VAD的持续时间对预后无明显影响。

本研究结果显示,近二十年来,儿童的心脏机械支持技术发展迅速,为小儿心脏移植提供了有力保障,但在新生儿和先心病患者中还存在很多挑战。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854102, encodeId=67cd185410231, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 18 07:38:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325906, encodeId=842d132590693, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jul 23 01:38:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333286, encodeId=d58a3332862a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 22 07:21:47 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333147, encodeId=516b33314ea5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:36 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-12-18 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854102, encodeId=67cd185410231, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 18 07:38:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325906, encodeId=842d132590693, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jul 23 01:38:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333286, encodeId=d58a3332862a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 22 07:21:47 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333147, encodeId=516b33314ea5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:36 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854102, encodeId=67cd185410231, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 18 07:38:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325906, encodeId=842d132590693, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jul 23 01:38:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333286, encodeId=d58a3332862a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 22 07:21:47 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333147, encodeId=516b33314ea5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:36 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-22 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1854102, encodeId=67cd185410231, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 18 07:38:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325906, encodeId=842d132590693, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Jul 23 01:38:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333286, encodeId=d58a3332862a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Jul 22 07:21:47 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333147, encodeId=516b33314ea5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:36 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 医者仁心5538

    学习了

    0

相关资讯

JACC:冠心病的生物标志物筛选

寻找引起冠心病(CAD)的生物标志物对其防治有重要意义。本研究的目的旨在通过孟德尔随机分析(MR)在237个生物标志物中筛选出引起CAD的生物标志物。本研究对ORIGIN临床研究中的4147名研究对象进行227个生物标志物的遗传决定性MR分析,并结合CARDIoGRAM团队(60801例病人和123504例对照)中的CAD分析结果。经多假设检验调整后发现,有6个生物标志物与CAD建立了相关性,其中

盘点:JACC7月第3期研究一览

1. 非甾体类抗炎药可增加房颤患者出血和住院风险DOI: 10.1016/j.jacc.2018.04.063http://www.onlinejacc.org/content/72/3/255非甾体类抗炎药(NSAIDs)是常见的药物,但可能增加潜在的出血和血栓形成风险。本研究的目的旨在量化NSAIDs在RE-LY临床试验中的作用。本研究是探究NSAIDs在RE-LY临床试验中作用的事后分析

JACC:仅少数心衰患者的药物和剂量使用符合指南推荐标准

指南对于射血分数减少型心衰(HFrEF)患者,强烈推荐接受药物联合治疗以改善预后,然而,对于门诊病人药物的使用和剂量的控制尚不清楚。本研究的目的旨在评估HFrEF药物使用和剂量的模式和相关影响因素。CHAMP-HF数据库纳入了美国至少接受有一种心衰药物治疗的慢性心衰门诊患者。最终,本研究共纳入3518名患者,平均年龄为66 ± 13岁,女性占29%,平均射血分数(EF)为29 ± 8%。分析结果显

JACC:经导管主动脉瓣置换术在外科主动脉瓣置换术失败患者中安全有效

经导管主动脉瓣置换术(ViV-TAVR)是切实可行的,然而其安全性与有效性和自体瓣膜TAVR(NV-TAVR)相比如何尚不清楚。本研究的目的旨在评估ViV-TAVR在外科主动脉瓣置换术(SAVR)失败患者中的安全性和有效性,并与NV-TAVR进行比较。本研究纳入了1150名接受ViV-TAVR治疗的患者,并1:2匹配了2259名接受NV-TAVR治疗的患者。非调整分析结果显示,与NV-TAVR患者

JACC:SGLT-2抑制剂可否降低2型糖尿病患者的心血管事件风险?

使用口服抗凝药(OACs)进行卒中预防是房颤管理的基础。然而,年龄≥90岁的患者使用OACs的数据有限。2018年7月,发表于《Circulation》上的一项队列研究,考察了OACs对老老年房颤(AF)患者的影响。

J Rheumatol:系统性红斑狼疮女性患者的孕前心血管健康和妊娠结局

差/中等的孕前心血管健康影响SLE女性患者早产和SGA婴儿的妊娠结局。